Investor Relations

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a pivotal Phase 2 clinical trial for EBV-positive (EBV+) lymphoma and a Phase 1b/2 trial in patients with EBVnasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

May Corporate Presentation

Stock Info
NASDAQVIRX
Recent News
May 13, 2022

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Compensation Committee of Viracta's Board of Directors...

May 11, 2022

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and participate in one-on-one...

May 10, 2022

Continued global expansion of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) that have advanced into Stage...

View All

Events
Wednesday, April 27, 2022
11:00am EDT

The webinar features a presentation from Key Opinion Leader (KOL) Ezra Cohen, MD, FRCPSC, FASCO (Chief of Hematology/Oncology, Department of Medicine and Co-director of the Gleiberman Head and Neck Cancer Center, University of California, San Diego), who discusses the current treatment landscape in nasopharyngeal carcinoma (NPC) and the Viracta management team discusses the potential of Viracta’s all-oral combination product Nana-val (nanatinostat and valganciclovir) to address the unmet needs of NPC patients with EBV+ disease. A Q&A session follows the formal presentations. 

A link the webcast replay is here: https://lifesci.events/VIRX2

View All

Investor Contact

Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com